TLDR:
- Life sciences venture capital firm venBio closed a $528 million fund oversubscribed.
- The fund will focus on biopharmaceutical companies developing treatments for unmet medical needs.
In a recent announcement, venBio, a life sciences venture capital firm, revealed the closing of their venBio Global Strategic Fund V, raising approximately $528 million in capital commitments. The fund, which exceeded its initial target, attracted a diverse group of institutional investors, including sovereign wealth funds, corporate pensions, university endowments, and family offices, among others.
Under the leadership of Managing Partners Dr. Richard Gaster, Dr. Corey Goodman, and Dr. Aaron Royston, Fund V will maintain venBio’s focus on biopharmaceutical companies developing treatments for unmet medical needs. The firm takes a hands-on approach, providing strategic guidance across research, clinical, and business activities to portfolio companies. They seek out opportunities that can provide meaningful clinical data and value within three to five years.
Dr. Royston highlighted the firm’s success in assisting companies in achieving nine FDA drug approvals over the past six years, generating significant value for venBio and its partners. Dr. Goodman emphasized the impact of their portfolio on patient lives, stating that Fund V is structured to continue their proven approach of selective company building.
Since its founding in 2011, venBio has raised approximately $2 billion in capital commitments and led investment rounds in over 40 companies. Some notable exits include acquisitions of Aragon Pharmaceuticals, Labrys Biologics, and Seragon Pharmaceuticals by major pharmaceutical companies like Johnson & Johnson, Teva, and Roche, respectively.
This successful fund close comes shortly after Amulet Capital Partners closed its third fund with $1.2 billion, indicating a potential resurgence of investor interest in the life sciences sector. With a track record of successful investments and a focused approach, venBio appears well-positioned to continue its growth and impact in the industry.
